The Thai Journal of Veterinary Medicine


Six dogs were diagnosed with pulmonary hypertension (PH) secondary to chronic degenerative mitral valve disease (CDMVD) on echocardiography. Imatinib (3 mg/kg, every 24 hours, PO) was initiated without any changes to the background therapy to treat the PH. Follow-up evaluations at 1, 3, 5 and 6 months revealed substantial clinical and hemodynamic improvements. One dog showed deterioration after the imatinib withdrawal to necessitate a restart therapy. No side effects were observed throughout the 6-month treatment course. Low-dose imatinib may provide a promising treatment alternative for CDMVD-associated PH in dogs.

First Page


Last Page